Zileuton

Lancet

Volumn 348, Issue 9026, 1996, Pages 519-524

  McGill, Kelly A ^a   Busse, William W ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BRONCHODILATING AGENT; HISTAMINE; LEUKOTRIENE; LEUKOTRIENE B4; LEUKOTRIENE E4; LIPOXYGENASE; PROSTAGLANDIN; THROMBOXANE; ZILEUTON;

AIRWAY OBSTRUCTION; ALLERGIC RHINITIS; ASTHMA; CLINICAL TRIAL; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DYSPEPSIA; ENZYME INHIBITION; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LEUKOPENIA; LIVER TOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SHORT SURVEY; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0030600338     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(95)12297-4     Document Type: Article

References (38)

1. 1 Burney PGJ, Chinn S, Rona RJ. Has the prevalence of asthma increased in children? Evidence from the national study of health and growth 1973-1986. BMJ 1990; 300: 1306-10.
2. 2 Jackson RJ, Sears MR, Beaglehole R, et al. International trends in asthma mortality: 1970 to 1985. Chest 1988; 94: 914-18.
3. 3 Weiss KB, Gergen PJ, Hodgson TA. The economic evaluation of asthma in the United States. N Engl J Med 1992; 326: 862-66.
4. 4 Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990; 336: 1391-96.
5. 5 Barnes PJ, Chung KF, Page CP. Inflammatory mediators and asthma. Pharmacol Rev 1988; 40: 49-84.
6. 6 Piacentini GL, Kaliner MA. The potential roles of leukotrienes in bronchial asthma. Am Rev Respir Dis 1991; 143: S96-99.
7. 7 Marom Z, Shellhamer JH, Back MK, et al. Slow reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis 1982; 126: 449-51.
8. 8 Henderson WR. The role of leukotrienes in inflammation. Ann Intern Med 1994; 121: 684-97.
9. 9 Dahlen SE, Hedqvist P, Hammarstrom S, et al. Leukotrienes are potent constrictors of human bronchi. Nature 1980; 228: 484-86.
10. 10 Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. N Engl J Med 1990; 323: 645-55.
11. 4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis 1990; 142: 112-19.
12. 4 levels following allergen and exercise challenge in bronchial asthma. Am Rev Respir Dis 1991; 144: 1411-13.
13. 13 Knapp HR, Sladek K, FitzGerald GA. Increased excretion of leukotriene E4 during aspirin-induced asthma. J Lab Clin Invest 1992; 119: 48-51.
14. 14 Dahlen SE, Hannson G, Hedqvist P, et al. Allergen challenge of lung tissue from asthmatics elicits bronchial constriction that correlates with the release of leukotrienes C4, D4, and E4. Proc Natl Acad Sci USA 1983; 80: 1712-16.
15. 15 Israel E, Rubin P, Kemp JP, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild to moderate asthma. Ann Intern Med 1993; 119: 1059-66.
16. 16 Knapp HR. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N Engl J Med 1990; 323: 1745-48.
17. 17 Weinblatt ME, Kremer JM, Coblyn JS, et al. Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis. J Rheumatol 1992; 19: 1537-41.
18. 18 Hackshaw KV, Shi Y, Brandwein SR, et al. A pilot study of zileuton, a novel selective 5-lipoxygenase inhibitor, in patients with systemic lupus erythematosus. J Rheumatol 1995; 22: 462-68.
19. 19 Laitinen LA, Laitinen A, Haahtela T, et al. Leukotriene E4 and granulocyte infiltration into asthmatic airways. Lancet 1993; 341: 989-90.
20. 20 Busse WW, Gaddy JN. The role of leukotriene antagonists and inhibitors in the treatment of airway disease. Am Rev Respir Dis 1991; 143: S103-07.
21. 21 Miller DK, Gillard JW, Vickers PJ, et al. Identification and isolation of a membrane protein necessary for leukotriene production. Nature 1990; 343: 278-81.
22. 22 Samuelsson B, Dahlen SE, Lindgren JA, et al. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987; 237: 1171-76.
23. 23 Orning L, Kaijser L, Hammerstrom S. In vivo metabolism of leukotriene C4 in man: urinary excretion of leukotriene E4. Biochem Biophys Res Commun 1985; 130: 214-20.
24. 24 Lewis MA, Mong S, Vessella RL, et al. Identification and characterization of leukotriene D4 receptors in adult and fetal human lung. Biochem Pharmacol 1985; 34: 3411-17.
25. 25 Bell RL, Young PR, Albert D, et al. The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor. Int J Immunopharmacol 1992; 14: 505-10.
26. 26 Rubin P, Dubé L, Braeckman R, et al. Pharmacokinetics, safety, and ability to diminish leukotriene synthesis by zileuton, an inhibitor of 5-lipoxygenase. AAS 1991; 35: 103-16.
27. 27 Sweeny DJ, Nellans HN. Stereoselective glucuronidation of zileuton isomers by human hepatic microsomes. Drug Metab Disp 1995; 23: 149-53.
28. 28 Israel E, Dermarkarian R, Rosenberg M, et al. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med 1990; 323: 1740-44.
29. 29 Fischer AR, McFadden CA, Frantz R, et al. Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects. Am J Respir Crit Care Med 1995; 152: 1203-07.
30. 30 Hui KP, Taylor IK, Taylor GW, et al. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax 1991; 46: 184-89.
31. 31 Lee TH. Mechanisms of aspirin sensitivity. Am Rev Respir Dis 1992; 145: 534-36.
32. 32 Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993; 148: 1447-51.
33. 33 Fischer AR, Rosenberg MA, Lilly CM, et al. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. J Allergy Clin Immunol 1994; 94: 1046-56.
34. 34 Israel E, Cohn J, Dubé L, et al. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. JAMA 1996; 275: 931-36.
35. 35 Martin R, Cicutto LC, Smith HR, et al. Airways inflammation in nocturnal asthma. Am Rev Respir Dis 1991; 143: 351-57.
36. 36 Wenzel SE, Trudeau JB, Kaminsky DA, et al. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am J Respir Crit Care Med 1995; 152: 897-905.
37. 37 Laursen LS, Naesdal J, Bukhave K, et al. Selective 5-lipoxygenase inhibition in ulcerative colitis. Lancet 1990; 335: 683-85.
38. 38 St Peter JV, Braeckman RA, Granneman GR, et al. The effect of zileuton on antipyrine and indocyanine green disposition. Clin Pharmacol Ther 1995; 57: 299-308.